Introduction
Gene One has built an organization that has developed a gene technology that eradicates disease in tomatoes and potatoes. The gene technology has helped many farmers and aided in the success of Gene One achieving 400 million in eight years of business. The Chief Executive Officer (CEO), Don Ruiz and the Board of Directors (Board) believe that to continue to grow 40 percent in each of the consecutive years, the organization will need to do an initial public offering (IPO). Gene One has a goal of meeting the IPO deadline within 3 years of beginning the process.
The objective of this paper is to examine Gene Ones recent decision to become a public company. Taking an organization public is a new venture for the current team of employees and this paper will look at the opportunities and challenges that currently exist along with market research. Finally the challenges and opportunities will be compared with the end stated goals.
Challenges and Opportunities
According to Ernst and Young's 19th Annual Global Biotechnology Report, nearly 30 years after the first biotechnology company opened its doors; the sector is reaching a new level of maturity and globalization. While all business shares the same desire to maximize profits regardless of being private or public, there is a different rule set for each course. Private companies can react more quickly to challenges and opportunities without going through the many layers of decision-making processes. With a public company, decisions are open to more scrutiny as investors demand accountability. A private firm is more inclined to take a long-term strategic view because the firm is not under quarter-to-quarter pressure from analysts and shareholders (Charles Jones).
After a series of corporat ...